Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium

Clinical Drug Investigation

Volumn 26, Issue 2, 2006, Pages 75-90

  De Ridder, Annemieke ^a   De Graeve, Diana ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE;

ACADEMIC ACHIEVEMENT; ANALYSIS OF COVARIANCE; ARTICLE; ATTENTION DEFICIT DISORDER; BELGIUM; CONTROLLED STUDY; DEMOGRAPHY; EMERGENCY WARD; GENERAL PRACTITIONER; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MEDICAL RECORD; PILOT STUDY; PRIORITY JOURNAL; PROBABILITY; QUESTIONNAIRE; RATING SCALE; REIMBURSEMENT; SIBLING; SOCIAL ASPECT; SOCIAL CARE; STATISTICAL MODEL;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COST OF ILLNESS; COSTS AND COST ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MULTIVARIATE ANALYSIS;

EID: 33244458022     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626020-00003     Document Type: Article

References (31)

1. Klassen A, Miller A, Raina P, et al. Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 1999; 44: 1007-16
2. Zametkin AJ, Ernst M. Problems in the management of attention-deficit hyperactivity disorder. N Engl J Med 1999; 340 (1): 40-6
3. Guidance on the use of methylphenidate for ADHD [online]. Available from URL: http: //www.nice.org.uk [Accessed 2001 Oct 27]
4. Noe LL, Hankin C. Health outcomes of childhood attention-deficit hyperactivity disorder (ADHD): healthcare use and status of caregivers [poster]. International Society for Pharmacoeconomics and Outcomes Research, 6th Annual Meeting; 2001 May 20-23; Arlington (VA)
5. Gilmore A, Milne R. Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf 2001; 10: 85-94
6. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther 2001; 23: 1904-21
7. Hankin CS, Wright A, Gephart H. The burden of attention-deficit/ hyperactivity disorder. Behavioral Health Trends 2001; 13 (4): 7-14
8. Zupanic JAF, Miller A, Raina P, et al. A review of therapies for ADHD. Part III: Economic evaluation of pharmaceutical and psychological/behavioural therapies for attention-deficit/hyperactivity disorder. Report to the Canadian Coordinating Office of Health Technology Assessment, p.172
9. Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/ hyperactivity disorder. JAMA 2001; 285: 60-6
10. Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperac-tivity disorder. Pediatrics 2001; 108: 71-8
11. Burd L, Klug MG, Coumbe MJ, et al. Children and adolescents with attention-deficit/hyperactivity disorder: 1. Prevalence and cost of care. J Child Neurol 2003; 18 (8): 555-61
12. Chan E, Zhan C, Homer C. Health care use and cost of children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2002; 156: 504-51
13. Kelleher KJ, Childs GE, Harman JS. Health care costs for children with attention-deficit/hyperactivity disorder. Econ Neurosci 2001; 3(4): 60-3
14. Guevara JP, Mandell DS. Costs associated with attention deficit hyperactivity disorder: overview and future projections. Expert Rev Pharmacoecon Outcomes Res 2003; 3 (2): 201-10
15. Leibson CL, Long KH. Economic implications of attention-deficit hyperactivity disorder for healthcare systems. Pharmaco- economics 2003; 21 (17): 1239-62
16. Milich R, Loney J, Landau S. Independent dimensions of hyperactivity and aggression: validation with playroom observation data. J Abnorm Child Psychol 1982; 3: 217-30
17. Cohen L, Kelly PC, Atkinson AW. Parent, teacher, child: a trilateral approach to attention-deficit disorder. Am J Dis Child 1989; 143 (10): 1229-33
18. Pelham WE, Milich R, Murphy DA, et al. Normative data on the IOWA Conners Teacher Rating Scale. J Clin Child Psychol 1989; 18 (3): 259-62
19. Data sent to us by RIZIV (Rijksinstituut voor ziekte- en invaliditeitsverzekering {Health Insurance Institute]) by email on 17 September 2003
20. Rice N, Jones A. Multilevel models and health economics. Health Econ 1997; 6: 561-75
21. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001; 20: 461-94
22. Thompson SG, Barber JA. How should cost data in pragmatic randomized trials be analysed? BMJ 2000; 320: 1197-200
23. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004; 23: 525-42
24. Manning GM, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ 2005; 24: 465-88
25. Manning WG. The logged dependent variable, heteroskedasticity, and the retransformation problem. J Health Econ 1998; 17: 283-95
26. Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J Health Serv Policy 2004; 9 (4): 197-204
27. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6 (1): 93-109
28. Basu A, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? Health Econ 2004; 13: 749-65
29. Tarifering van de Geneeskundige Verstrekkingen 2002. Studiecentrum voor Cöordinatie en Verspreiding
30. Mutualit́es Libres/Onafhankelijke ziekenfondsen (MLOZ): Vergoeding van geneeskundige verstrekkingen [online]. Available from URRL: http://www.mloz.be [Accessed Sep 5 2003]
31. Gezondheidsenqûete 2001: Gezondheidsenqûete door middel van interview Belgïe 2001 [online]. Available from URRL: http://www.iph.fgov. be/sasweb/his/nl/ [Accessed Feb 2 2004]